Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-13 1:14 pm Sale | 2024-09-30 | 13G | G1 Therapeutics, Inc. GTHX | Beryl Capital Management LLC | 0 0.000% | -5,179,529 (Position Closed) | Filing History |
| 2024-08-19 7:02 pm Purchase | 2024-08-07 | 13G | G1 Therapeutics, Inc. GTHX | Beryl Capital Management LLC | 5,179,529 9.800% | 5,179,529 (New Position) | Filing History |
| 2024-02-21 4:30 pm Purchase | 2022-11-18 | 13D | G1 Therapeutics, Inc. GTHX | ESHELMAN FREDRIC N | 4,766,074 9.260% | 1,072,479 (+29.04%) | Filing History |
| 2024-02-05 3:37 pm Purchase | 2023-05-08 | 13G | G1 Therapeutics, Inc. GTHX | Fisher Asset Management LLC | 1,000 0.000% | 1,000 (New Position) | Filing History |
| 2023-02-09 11:19 am Sale | 2022-12-30 | 13G | G1 Therapeutics, Inc. GTHX | VANGUARD GROUP INC | 1,925,845 3.810% | -618,520 (-24.31%) | Filing History |
| 2023-02-03 11:47 am Purchase | 2022-12-31 | 13G | G1 Therapeutics, Inc. GTHX | STATE STREET CORP STT | 179,736 0.360% | 37,530 (+26.39%) | Filing History |
| 2022-12-06 10:35 am Sale | 2022-11-30 | 13G | G1 Therapeutics, Inc. GTHX | JPMORGAN CHASE & CO JPM | 2,045,814 4.000% | -94,034 (-4.39%) | Filing History |
| 2022-07-11 1:20 pm Sale | 2022-06-30 | 13G | G1 Therapeutics, Inc. GTHX | STATE STREET CORP STT | 142,206 0.330% | -4,159,407 (-96.69%) | Filing History |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | G1 Therapeutics, Inc. GTHX | BlackRock Inc. BLK | 1,369,281 3.200% | -1,940,931 (-58.63%) | Filing History |
| 2022-02-11 08:12 am Sale | 2021-12-31 | 13G | G1 Therapeutics, Inc. GTHX | STATE STREET CORP STT | 4,301,613 10.120% | -81,999 (-1.87%) | Filing History |
| 2022-02-10 08:11 am Purchase | 2021-12-31 | 13G | G1 Therapeutics, Inc. GTHX | VANGUARD GROUP INC | 2,544,365 5.980% | 448,638 (+21.41%) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | G1 Therapeutics, Inc. GTHX | BlackRock Inc. BLK | 3,310,212 7.800% | 416,619 (+14.40%) | Filing History |
| 2022-01-21 11:43 am Purchase | 2021-12-31 | 13G | G1 Therapeutics, Inc. GTHX | JPMORGAN CHASE & CO JPM | 2,139,848 5.000% | 2,139,848 (New Position) | Filing History |
| 2021-10-12 12:30 pm Purchase | 2021-09-30 | 13G | G1 Therapeutics, Inc. GTHX | STATE STREET CORP STT | 4,383,612 10.350% | 1,803,793 (+69.92%) | Filing History |
| 2021-02-12 4:16 pm Sale | 2020-12-31 | 13G | G1 Therapeutics, Inc. GTHX | Hatteras Venture Partners IV SBIC LP | 1,756,462 4.600% | -259,926 (-12.89%) | Filing History |
| 2021-02-11 1:07 pm Purchase | 2020-12-31 | 13G | G1 Therapeutics, Inc. GTHX | STATE STREET CORP STT | 2,579,819 6.780% | 2,579,819 (New Position) | Filing History |
| 2021-02-10 10:57 am Purchase | 2020-12-31 | 13G | G1 Therapeutics, Inc. GTHX | VANGUARD GROUP INC | 2,095,727 5.510% | 82,162 (+4.08%) | Filing History |
| 2021-02-08 10:23 am Sale | 2021-02-05 | 13G | G1 Therapeutics, Inc. GTHX | FMR LLC | 923,939 2.428% | -1,620,598 (-63.69%) | Filing History |
| 2021-02-03 1:33 pm Sale | 2020-12-31 | 13G | G1 Therapeutics, Inc. GTHX | WELLINGTON MANAGEMENT GROUP LLP | 1,237,342 3.250% | -1,719,213 (-58.15%) | Filing History |
| 2021-01-29 09:57 am Purchase | 2020-12-31 | 13G | G1 Therapeutics, Inc. GTHX | BlackRock Inc. BLK | 2,893,593 7.600% | 313,234 (+12.14%) | Filing History |